Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

261 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
c-Jun N-Terminal Kinase Inactivation by Mitogen-Activated Protein Kinase Phosphatase 1 Determines Resistance to Taxanes and Anthracyclines in Breast Cancer.
Rincón R, Zazo S, Chamizo C, Manso R, González-Alonso P, Martín-Aparicio E, Cristóbal I, Cañadas C, Perona R, Lluch A, Eroles P, García-Foncillas J, Albanell J, Rovira A, Madoz-Gúrpide J, Rojo F. Rincón R, et al. Among authors: albanell j. Mol Cancer Ther. 2016 Nov;15(11):2780-2790. doi: 10.1158/1535-7163.MCT-15-0920. Epub 2016 Sep 6. Mol Cancer Ther. 2016. PMID: 27599524
Autocrine CCL5 Effect Mediates Trastuzumab Resistance by ERK Pathway Activation in HER2-Positive Breast Cancer.
Zazo S, González-Alonso P, Martín-Aparicio E, Chamizo C, Luque M, Sanz-Álvarez M, Mínguez P, Gómez-López G, Cristóbal I, Caramés C, García-Foncillas J, Eroles P, Lluch A, Arpí O, Rovira A, Albanell J, Madoz-Gúrpide J, Rojo F. Zazo S, et al. Among authors: albanell j. Mol Cancer Ther. 2020 Aug;19(8):1696-1707. doi: 10.1158/1535-7163.MCT-19-1172. Epub 2020 May 13. Mol Cancer Ther. 2020. PMID: 32404410
Preclinical and Clinical Characterization of Fibroblast-derived Neuregulin-1 on Trastuzumab and Pertuzumab Activity in HER2-positive Breast Cancer.
Guardia C, Bianchini G, Arpí-LLucià O, Menendez S, Casadevall D, Galbardi B, Dugo M, Servitja S, Montero JC, Soria-Jiménez L, Sabbaghi M, Peña R, Madoz-Gúrpide J, Lloveras B, Lluch A, Eroles P, Arribas J, Pandiella A, Gianni L, Rojo F, Rovira A, Albanell J. Guardia C, et al. Among authors: albanell j. Clin Cancer Res. 2021 Sep 15;27(18):5096-5108. doi: 10.1158/1078-0432.CCR-20-2915. Epub 2021 Aug 12. Clin Cancer Res. 2021. PMID: 34385295
mTOR Inhibition and T-DM1 in HER2-Positive Breast Cancer.
Casadevall D, Hernández-Prat A, García-Alonso S, Arpí-Llucià O, Menéndez S, Qin M, Guardia C, Morancho B, Sánchez-Martín FJ, Zazo S, Gavilán E, Sabbaghi MA, Eroles P, Cejalvo JM, Lluch A, Rojo F, Pandiella A, Rovira A, Albanell J. Casadevall D, et al. Among authors: albanell j. Mol Cancer Res. 2022 Jul 6;20(7):1108-1121. doi: 10.1158/1541-7786.MCR-21-0545. Mol Cancer Res. 2022. PMID: 35348729
Role of SALL4 in HER2+ Breast Cancer Progression: Regulating PI3K/AKT Pathway.
Pattanayak B, Lameirinhas A, Torres-Ruiz S, Burgués O, Rovira A, Martínez MT, Tapia M, Zazo S, Albanell J, Rojo F, Bermejo B, Eroles P. Pattanayak B, et al. Among authors: albanell j. Int J Mol Sci. 2022 Oct 31;23(21):13292. doi: 10.3390/ijms232113292. Int J Mol Sci. 2022. PMID: 36362083 Free PMC article.
261 results